Meredith McMorrow
YOU?
Author Swipe
View article: Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023–2024
Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023–2024 Open
Nirsevimab is recommended to prevent severe respiratory syncytial virus (RSV)-associated illness among American Indian/Alaska Native (AI/AN) children <20 months of age. In a test-negative case-control analysis among 291 AI/AN children hosp…
View article: Optimizing the sensitivity of detection of respiratory syncytial virus infections in longitudinal studies using the combination of weekly sample testing and biannual serology
Optimizing the sensitivity of detection of respiratory syncytial virus infections in longitudinal studies using the combination of weekly sample testing and biannual serology Open
Cohort studies are often challenged by incomplete adherence to sampling regimens, limiting the full capture of disease burden. We describe the detection of respiratory syncytial virus (RSV) infections achieved in a birth cohort using a com…
View article: Clinical Testing for COVID-19, Influenza, and RSV in Hospitalized Youths, 2016-2024
Clinical Testing for COVID-19, Influenza, and RSV in Hospitalized Youths, 2016-2024 Open
Importance Studies of COVID-19, influenza, and respiratory syncytial virus (RSV) disease clinical epidemiology, disease burden, and vaccine effectiveness often rely on clinical testing to identify cases, particularly with increasing use of…
View article: Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025 Open
Before the introduction of universal respiratory syncytial virus (RSV) immunization recommendations for infants, RSV was the leading cause of hospitalization among infants in the United States. Since 2023, CDC's Advisory Committee on Immun…
View article: Incidence Rates of COVID-19-Associated Hospitalization and Risk Factors for Severe Disease Among American Indian and Alaska Native Persons in the Southwest USA and Alaska
Incidence Rates of COVID-19-Associated Hospitalization and Risk Factors for Severe Disease Among American Indian and Alaska Native Persons in the Southwest USA and Alaska Open
Introduction COVID-19 causes significant morbidity in the USA, particularly among American Indian/Alaska Native (AI/AN) persons. Estimates of COVID-19 burden among AI/AN communities are needed to identify health outcome disparities and inf…
View article: Bordetella pertussis infection and antibody dynamics in household cohorts in two South African communities, 2016 – 2018: findings from the PHIRST study
Bordetella pertussis infection and antibody dynamics in household cohorts in two South African communities, 2016 – 2018: findings from the PHIRST study Open
View article: Temporal Changes in Nasopharyngeal Pneumococcal Colonization Density Associated With Respiratory Syncytial Virus and Influenza in a South African Household Cohort Study, 2016–2018
Temporal Changes in Nasopharyngeal Pneumococcal Colonization Density Associated With Respiratory Syncytial Virus and Influenza in a South African Household Cohort Study, 2016–2018 Open
Background Respiratory syncytial virus (RSV) and influenza infections are associated with increased pneumococcal colonization and disease risk. We assessed the impact of RSV and influenza on pneumococcal colonization density and factors in…
View article: Enterovirus D68–Associated Respiratory Illness in Children
Enterovirus D68–Associated Respiratory Illness in Children Open
Importance Enterovirus D68 (EV-D68) typically causes mild to severe acute respiratory illness (ARI). Testing and surveillance for EV-D68 in the US are limited, and important epidemiologic gaps remain. Objective To characterize the epidemio…
View article: Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season
Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season Open
View article: Using Multiple Methods to Estimate Respiratory Syncytial Virus (RSV)‐associated Hospitalization Rates in Children Aged < 5 Years—Hamilton County, Ohio, 2009–2017
Using Multiple Methods to Estimate Respiratory Syncytial Virus (RSV)‐associated Hospitalization Rates in Children Aged < 5 Years—Hamilton County, Ohio, 2009–2017 Open
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in children less than 5 years of age worldwide. In the United States, RSV commonly causes hospitalization in young children and is the lea…
View article: Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025
Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025 Open
COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2…
View article: P-1212. Enterovirus D68 (EV-D68) Incidence and Spectrum of Illness among Children 0-2 years in a U.S. Community-based Birth Cohort in Cincinnati, OH during 2017-2020
P-1212. Enterovirus D68 (EV-D68) Incidence and Spectrum of Illness among Children 0-2 years in a U.S. Community-based Birth Cohort in Cincinnati, OH during 2017-2020 Open
Background The community burden and epidemiology of non-medically attended enterovirus-D68 (EV-D68) is unknown, as prior studies focus on EV-D68-associated asthma exacerbation, pneumonia, or acute flaccid myelitis (AFM) which occurs bienni…
View article: P-710. Epidemiology of RSV infections in a birth cohort of healthy children, PREVAIL Cohort 2017-2020
P-710. Epidemiology of RSV infections in a birth cohort of healthy children, PREVAIL Cohort 2017-2020 Open
Background Acute bronchiolitis due to respiratory syncytial virus (RSV) is the leading cause of hospitalizations in infants in the United States. Most available data on RSV epidemiology were obtained from hospital cohorts or medically atte…
View article: Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season
Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season Open
Nirsevimab is a long-acting monoclonal antibody that protects infants and young children against severe respiratory syncytial virus (RSV) disease. Children are eligible for one 50 mg dose, one 100 mg dose, or two 100 mg doses of nirsevimab…
View article: Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023
Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023 Open
Background Assessments of COVID‐19 vaccine effectiveness are needed to monitor the protection provided by updated vaccines against severe COVID‐19. We evaluated the effectiveness of original monovalent and bivalent (ancestral strain and Om…
View article: Effectiveness of the Original Monovalent Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination Series Against Hospitalization for COVID-19–Associated Venous Thromboembolism
Effectiveness of the Original Monovalent Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination Series Against Hospitalization for COVID-19–Associated Venous Thromboembolism Open
Background Coronavirus disease 2019 (COVID-19) is a strong risk factor for venous thromboembolism (VTE). Few studies have evaluated the effectiveness of COVID-19 vaccination in preventing hospitalization for COVID-19 with VTE. Methods Adul…
View article: RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older
RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older Open
This study evaluates the effectiveness of the respiratory syncytial virus vaccine against hospitalization for acute respiratory illness among US adults aged 60 years and older.
View article: RSV burden and prevention in children in LMICs
RSV burden and prevention in children in LMICs Open
View article: SARS-CoV-2 correlates of protection from infection against variants of concern
SARS-CoV-2 correlates of protection from infection against variants of concern Open
View article: SARS-CoV-2 correlates of protection from infection against variants of concern
SARS-CoV-2 correlates of protection from infection against variants of concern Open
Serum neutralizing antibodies (nAbs) induced by vaccination have been linked to protection against symptomatic COVID-19 and severe disease. However, much less is known about the efficacy of nAbs in preventing the acquisition of infection, …
View article: Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults
Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults Open
Importance On June 21, 2023, the Centers for Disease Control and Prevention recommended the first respiratory syncytial virus (RSV) vaccines for adults aged 60 years and older using shared clinical decision-making. Understanding the severi…
View article: Characteristics of infections with ancestral, Beta and Delta variants of SARS-CoV-2 in the PHIRST-C community cohort study, South Africa, 2020-2021
Characteristics of infections with ancestral, Beta and Delta variants of SARS-CoV-2 in the PHIRST-C community cohort study, South Africa, 2020-2021 Open
View article: Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024 Open
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for…
View article: Endemic Coronavirus Infections are Associated with Strong Homotypic Immunity in a US Cohort of Children from Birth to 4 Years
Endemic Coronavirus Infections are Associated with Strong Homotypic Immunity in a US Cohort of Children from Birth to 4 Years Open
Background The endemic coronaviruses OC43, HKU1, NL63, and 229E cause cold-like symptoms and are related to SARS-CoV-2, but their natural histories are poorly understood. In a cohort of children followed from birth to 4 years, we documente…
View article: <i>Notes from the Field:</i>Reemergence of<i>Mycoplasma pneumoniae</i>Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018–2024
<i>Notes from the Field:</i>Reemergence of<i>Mycoplasma pneumoniae</i>Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018–2024 Open
View article: Seasonality, Clinical Characteristics, and Outcomes of Respiratory Syncytial Virus Disease by Subtype Among Children Aged &lt;5 Years: New Vaccine Surveillance Network, United States, 2016–2020
Seasonality, Clinical Characteristics, and Outcomes of Respiratory Syncytial Virus Disease by Subtype Among Children Aged <5 Years: New Vaccine Surveillance Network, United States, 2016–2020 Open
Background Respiratory syncytial virus (RSV) is a leading cause of acute respiratory illnesses in children. RSV can be broadly categorized into 2 major subtypes: A and B. RSV subtypes have been known to cocirculate with variability in diff…
View article: Factors Associated With Prolonged Respiratory Virus Detection From Polymerase Chain Reaction of Nasal Specimens Collected Longitudinally in Healthy Children in a US Birth Cohort
Factors Associated With Prolonged Respiratory Virus Detection From Polymerase Chain Reaction of Nasal Specimens Collected Longitudinally in Healthy Children in a US Birth Cohort Open
Background Respiratory viral shedding is incompletely characterized by existing studies due to the lack of longitudinal nasal sampling and limited inclusion of healthy/asymptomatic children. We describe characteristics associated with prol…
View article: Epidemiology of Human Seasonal Coronaviruses Among People With Mild and Severe Acute Respiratory Illness in Blantyre, Malawi, 2011–2017
Epidemiology of Human Seasonal Coronaviruses Among People With Mild and Severe Acute Respiratory Illness in Blantyre, Malawi, 2011–2017 Open
Background The aim of this study was to characterize the epidemiology of human seasonal coronaviruses (HCoVs) in southern Malawi. Methods We tested for HCoVs 229E, OC43, NL63, and HKU1 using real-time polymerase chain reaction (PCR) on upp…
View article: An evaluation of an influenza vaccination campaign targeting pregnant women in 27 clinics in two provinces of South Africa, 2015 -- 2018.
An evaluation of an influenza vaccination campaign targeting pregnant women in 27 clinics in two provinces of South Africa, 2015 -- 2018. Open
Introduction Despite prioritization, routine antenatal influenza vaccine coverage is <16% in South Africa. We aimed to describe maternal influenza vaccine coverage in 27 antenatal clinics (ANCs) in Gauteng and Western Cape (WC) Provinces, …
View article: SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis
SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis Open